Lyell Immunopharma, Inc. Common Stock (LYEL) Stock Price

LYELStock

$8.12−52.24%52W

Market Cap$198.98M

P/E—

PEG Ratio—

Div yield—

Beta-0.03

LYEL Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-75.16%

Price vs S&P 500 (4W)-24.38%

VGM Score23.49

Book Value / Share (Quarterly)$9.99

P/TBV (Annual)0.51x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-92.48%

Cash Flow / Share (Quarterly)$-7.49

Price vs S&P 500 (YTD)-85.55%

Net Profit Margin (TTM)-920285.19%

EPS (TTM)$-12.01

10-Day Avg Trading Volume0.20M

EPS Excl Extra (TTM)$-12.01

Revenue Growth (5Y)-65.86%

EPS (Annual)$-16.06

ROI (Annual)-110.57%

Net Profit Margin (5Y Avg)-301538.54%

Cash / Share (Quarterly)$8.72

Revenue Growth QoQ (YoY)-50.00%

ROA (Last FY)-80.71%

Revenue Growth TTM (YoY)-55.00%

EBITD / Share (TTM)$-11.76

ROE (5Y Avg)-56.98%

Operating Margin (TTM)-949981.48%

Cash Flow / Share (Annual)$-9.03

P/B Ratio0.85x

P/B Ratio (Quarterly)1.40x

Net Income / Employee (Annual)$-1,704,600

EV / Revenue (TTM)4666.54x

ROA (TTM)-70.50%

EPS Incl Extra (Annual)$-16.06

Current Ratio (Annual)5.28x

Quick Ratio (Quarterly)5.12x

3-Month Avg Trading Volume0.18M

52-Week Price Return-52.24%

Revenue / Employee (TTM)$200

Tangible BV / Share (Quarterly)$2.77

P/S Ratio (Annual)5527.27x

Asset Turnover (Annual)0.00x

52-Week High$45.00

Operating Margin (5Y Avg)-312062.62%

EPS Excl Extra (Annual)$-16.06

CapEx CAGR (5Y)-4.00%

26-Week Price Return-65.25%

Quick Ratio (Annual)5.00x

13-Week Price Return-39.04%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.36x

Enterprise Value$126.00M

Revenue / Share Growth (5Y)-42.00%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$200

Pretax Margin (Annual)-762355.56%

Cash / Share (Annual)$11.63

3-Month Return Std Dev63.09%

Net Income / Employee (TTM)$-1,543,300

ROE (Last FY)-110.57%

EPS Basic Excl Extra (Annual)$-16.06

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-12.01

ROI (TTM)-91.62%

P/S Ratio (TTM)7369.69x

Pretax Margin (5Y Avg)-301538.54%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$3.34

Price vs S&P 500 (52W)-67.77%

Year-to-Date Return-73.62%

5-Day Price Return-1.81%

EPS Normalized (Annual)$-16.06

ROA (5Y Avg)-44.72%

Net Profit Margin (Annual)-762355.56%

Month-to-Date Return-17.06%

Cash Flow / Share (TTM)$-0.67

EBITD / Share (Annual)$-15.09

Operating Margin (Annual)-748344.44%

ROI (5Y Avg)-56.98%

EPS Basic Excl Extra (TTM)$-12.01

P/TBV (Quarterly)0.61x

P/B Ratio (Annual)2.63x

Pretax Margin (TTM)-920285.19%

Book Value / Share (Annual)$11.68

Price vs S&P 500 (13W)-41.72%

Beta-0.03x

P/FCF (Annual)8.50x

Revenue / Share (TTM)$0.00

ROE (TTM)-91.62%

52-Week Low$7.20

vGradeD

gGradeF

mGradeD

vgmGradeD

LYEL Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 6, 2026	-$1.79	-$1.74	+2.87%(+$0.05)
Q1 2026	May 6, 2026	-$2.36	-$1.10	+53.47%(+$1.26)
Q4 2025	Mar 12, 2026	-$2.23	-$7.68	-244.09%(-$5.45)
Q3 2025	Nov 12, 2025	-$2.64	-$2.13	+19.39%(+$0.51)
Q2 2025	Aug 12, 2025	-$3.58	-$2.89	+19.35%(+$0.69)

LYEL Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

4.07

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
LYELLyell Immunopharma, Inc. Common Stock	D	F	D	7369.7x	-55.0%	—	—	$8.12
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Lyell Immunopharma, Inc. Common Stock

Lyell Immunopharma is a clinical-stage cell therapy company developing T-cell therapies for solid tumors through proprietary ex vivo genetic and epigenetic reprogramming technology. The company's pipeline includes three lead candidates: LYL797, LYL119, and LYL845.

LYEL Next Earnings Report

Report dateNov 6, 2026

QuarterQ3 2026

Report timeAMC

EPS estimate-$1.88

Revenue estimate$3,290

Also reporting on Nov 6, 2026

Scheduled date with consensus estimates — both can change before the company reports.

Earnings calendar for November 2026

LYEL Insider Transactions

SellOct 12, 2026
AGUIRRE JARRAD MATTIEU
Officer
Shares: 422Value: $3,642
SellSep 10, 2026
SHOOK DAVID M.D.
Officer
Shares: 500Value: $6,350
SellAug 21, 2026
SEELY LYNN
Chief Executive Officer
Shares: 9,589Value: $149,013
SellAug 21, 2026
LEE GARY K
Officer
Shares: 1,457Value: $22,642
SellAug 21, 2026
HILL STEPHEN J
Chief Operating Officer
Shares: 989Value: $15,369

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for October 2026

Companies in Related Industries

LXEOLexeo Therapeutics, Inc. Common StockBiological Products
FATEFate Therapeutics, Inc.Biological Products
PLXProtalix BioTherapeutics, Inc. Common StockBiological Products
ALECAlector, Inc. Common StockBiological Products
NAGENiagen Bioscience, Inc. Common StockPharmaceutical Preparations
CGENCompugen LtdBiological Products
LTBRLightbridge Corp.Industrial Chemicals
IVVDInvivyd, Inc. Common StockBiological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.1

Buy

Consensus rating

52-Week Range

Low$7.20

High$45.00